Table 2 Correlations between S1PR1 mRNA expression and clinical prognosis in breast cancer with respect to clinicopathological factors
From: Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers
Clinicopathological characteristics | Overall | ||
|---|---|---|---|
N | Hazard ratio | P-value | |
ER status | |||
 ER positive | 2061 | 0.79 (0.67–0.94) | 0.0057 |
 ER negative | 801 | 0.95 (0.7–1.18) | 0.62 |
PR status | |||
 PR positive | 589 | 0.91 (0.64–1.29) | 0.6024 |
 PR negative | 549 | 1.02 (0.76–1.36) | 0.9124 |
HER2 status | |||
 HER2 positive | 252 | 1.13 (0.73–1.75) | 0.5743 |
 HER2 negative | 800 | 0.75 (0.57–0.96) | 0.0247 |
Intrinsic subtype | |||
 Basal | 241 | 1.23 (0.75–2.01) | 0.41 |
 Luminal A | 611 | 0.75 (0.52–1.06) | 0.1 |
 Luminal B | 433 | 0.97 (0.67–1.41) | 0.88 |
 HER2+ | 147 | 0.67 (0.35–1.28) | 0.2235 |
Lymph node status | |||
 Lymph node positive | 313 | 0.94 (0.64–1.38) | 0.75 |
 Lymph node negative | 594 | 1.07 (0.73–1.55) | 0.74 |
Grade | |||
 1 | 345 | 0.68 (0.4–1.15) | 0.1461 |
 2 | 901 | 0.94 (0.74–1.2) | 0.63 |
 3 | 903 | 0.93 (0.75–1.16) | 0.5257 |
TP53 status | |||
 Mutated | 188 | 1.17 (0.73–1.88) | 0.52 |
 Wild type | 273 | 0.81 (0.42–1.54) | 0.52 |
Pietenpol subtype | |||
 Basal-like 1 | 58 | 1.69 (0.55–5.17) | 0.35 |
 Basal-like 2 | 38 | 0.96 (0.28–3.34) | 0.95 |
 Immunomodulatory | 100 | 1.67 (0.65–4.32) | 0.28 |
 Mesenchymal | 73 | 0.79 (0.36–1.73) | 0.56 |
 Mesenchymal stem -like | 19 | NA | NA |
 Luminal androgen receptor | 203 | 0.46 (0.3–0.71) | 0.0002 |
Systemically untreated patients | |||
 Include | 1402 | 0.86 (0.69–1.07) | 0.17 |
 Exclude | 3951 | 0.67 (0.6–0.75) | 7.1E-13 |